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Staphylococcus aureusThe ability of Staphylococcus aureus to form bioﬁlms is considered an important factor in the pathogenesis of
central venous catheter-related bacteremia and infections associated with the use of medical prostheses. Dif-
ferent methods have been described for assessing staphylococcal bioﬁlms, but few comparative studies have
been attempted to evaluate these techniques; especially related to ica-independent bioﬁlm formation/
accumulation. In this study we compared some in vitro and in vivo techniques to evaluate ica-independent
bioﬁlms produced by methicillin-resistant S. aureus. We observed that bioﬁlms formed on human
ﬁbronectin-covered surfaces were about three times higher than those produced on inert polystyrene
surfaces. However, despite the difference in absolute values, a linear correlation was detected between
these two models. We also found that bioﬁlms formed on polystyrene or polyurethane surfaces treated
with human serum were easily detachable during washing and staining processes. The mouse model of sub-
cutaneous foreign body showed good correlationwith the in vitro techniques using either inert polystyrene or
solid-phase ﬁbronectin. Thus, our data showed that themicrotiter-plate-based spectrophotometric assay is an
appropriate method for preliminary bioﬁlm investigations, mainly when a large number of isolates, mutants
or systems need to be tested.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a common
cause of hospital- and community-acquired infections worldwide
(Stefani and Goglio, 2010). The staphylococcal bioﬁlm is considered
an important virulence factor associated with the pathogenesis of
implantable device-related infections, contributing to increased
morbidity, mortality and healthcare costs (Bahna et al., 2007; Jain
and Agarwal, 2009). After insertion into the patients, medical devices
are rapidly coated with host-derived extracellular matrix compo-
nents and plasma proteins (including ﬁbrinogen, ﬁbronectin, colla-
gen, albumin and others), which can function as adhesion molecules
for microbial attachment (Edmiston et al., 2006; O'Neill et al., 2009).
Bacterial factors that have been implicated in cell–cell adhesion and
bioﬁlm accumulation comprise a series of both surface-attached and
secreted molecules, such as protein, polysaccharide and nucleic acid
(Otto, 2010). S. aureus surface-proteins responsible for mediating
attachment to host matrix components have commonly been referred
to as MSCRAMM (for microbial surface components recognizing
adhesive matrix molecules). Usually, these surface proteins display
functional redundancy, emphasizing their importance for S. aureus73, Rio de Janeiro, RJ, 21941-
do).
evier OA license.pathogenesis (Foster and Höök, 1998; Speziale et al., 2009). Following
the initial attachment, bioﬁlm is accumulated, forming a densely
packed community of adherent bacterial cells. This living form is
considered particularly advantageous because in the bioﬁlm environ-
ment microorganisms are often less responsive to antimicrobials and
host defense mechanisms (Bahna et al., 2007; Otto, 2010). There are
at least two types of bioﬁlms formed by S. aureus: ica-dependent
and ica-independent. ica-dependent is mediated by the polysaccha-
ride intercellular adhesion or poly-N-acetylglucosamine (PIA/PNAG),
which is synthesized by enzymes codiﬁed by icaADBC (O'Neill et al.,
2007; Vergara-Irigaray et al., 2009). Studies by O'Neill et al. (2007)
suggested that ica-dependent bioﬁlm was mainly associated with
methicillin-susceptible Staphylococcus aureus (MSSA) isolates.
However, the same study showed that glucose-induced bioﬁlm for-
mation by MRSA was mainly ica-independent and probably mediated
by proteins. Despite this knowledge, the composition of S. aureus
ica-independent bioﬁlms and the regulatory network that modulates
bioﬁlm production have not been fully elucidated thus far. The S.
aureus surface protein G (SasG) and its homologue plasmin-
sensitive surface protein (Pls), ﬁbronectin-binding proteins A ad B
(FnBPA and FnBPB) and staphylococcal protein A (Spa) have been im-
plicated in bioﬁlm accumulation (Savolainen et al., 2001; Corrigan et
al., 2007; Merino et al, 2009; O'Neill et al., 2009). In addition, other
proteins have been associated with S. aureus bioﬁlm formation/
accumulation — including the major aulolysin AtlA (Houston et al.,
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ases (Martí et al., 2010). The divergent effect of the Agr quorum-
sensing system on S. aureus bioﬁlm corroborates the hypothesis that
the mechanisms involved in bioﬁlm formation/accumulation are
complex and probably of multifactorial nature (Coelho et al., 2008).
In order to improve our knowledge on key processes associated
with bioﬁlm formation, accumulation and detachment, and with
bioﬁlm-speciﬁc regulatory pathways, the use of good quality bio-
ﬁlm–model systems is of fundamental importance (Coenye and
Nelis, 2010). The development of in vitro and in vivo models that ad-
equately reﬂect the real-life situation is of major interest (Cassat et
al., 2007; Coenye and Nelis, 2010). From the simple microtiter plate
assay to the 3D-bioﬁlm structure generated by confocal laser scan-
ning microscopy (CLSM), different tools for studying microbial bio-
ﬁlms have been reported including ﬂow cell systems, real-time
analysis of bioﬁlm formation using reporter gene assays, and a wide
variety of animal models (Harraghy et al., 2006). Despite that, there
are just few comparative studies on model systems for investigating
staphylococcal bioﬁlms (Cassat et al., 2007; Coenye and Nelis,
2010). In this work, we have compared the microtiter-plate-based
spectrophotometric assay with a mouse model of foreign body for
studying bioﬁlm formation/accumulation in S. aureus isolates.
2. Material and methods
2.1. S. aureus isolates
The 20 bioﬁlm-producing MRSA clinical isolates used in this study
were obtained from patients with catheter-associated blood stream
infection (CA-BSI), collected in 2007–2008, in Rio de Janeiro city hospi-
tals, except one isolate that was collected in 1997 from a hospital in
Miami, FL, USA. The isolate (BMB9393), obtained from a case of
pneumonia in 1999, was also included in this study for its superior abil-
ity to form/accumulate bioﬁlm. The isogenic agr knockout MNY19335
(Δagr::tetM) and the rnaIII-trans-complementation of the agr mutant
CMNY19335 (Δagr::tetM, pbla-rnaIII) were previously constructed
(Coelho et al., 2008). ica-independent bioﬁlm was assessed by disrupt-
ing preformed bioﬁlm with proteinase K (1 mg/mL) for 2 h at 37 °C. All
bacterial isolates and constructions were stored in 12% glycerol at
−70 °C.
This project was approved by the Human Research Ethics Commit-
tee from Clementino Fraga University Hospital, Federal University of
Rio de Janeiro (# 136/07-CEP).
2.2. In vitro bioﬁlm formation on inert surface (microtiter plate-based
model)
Bioﬁlm assays were performed in 96-well inert polystyrene micro-
titer plates (Nunclon; Nunc A/S, Roskilde, Denmark), using TSB (BD;
Becton, Dickinson and Company, Le Pont de Claix, France) supplemen-
ted with 1% (w/v) glucose (TSB-1% Glc) as described previously
(Coelho et al., 2008). Brieﬂy, bacteria were grown in TSB-1% Glc, in a
shaker (250 rpm) at 37 °C for 18 h. Subsequently, cultures were diluted
1:100 in TSB-1% Glc and 200 μl was inoculated into each well. The mi-
crotiter plate was incubated at 37 °C for 20 h. After incubation, super-
natants were removed from each well and bioﬁlms were gently
washed twice with 0.85% NaCl, dried and ﬁxed at 65 °C for 1 h. Finally,
the plates were stained with crystal violet (Gram-stain), gently washed
twice, and the absorbance determined using amicrotiter plate reader at
570 nm (Abioﬁlm). In parallel, the OD570 of 1/100 cultures in TSB-1% Glu
(incubated in static conditions at 37 °C for 20 h) was also determined
(Agrowth). The bioﬁlm unit (BU) was calculated using the following for-
mula: BU=Abioﬁlm/Agrowth. Based on the value obtained for the negative
control, the Streptococcus pyogenes isolate 75194 (BU=0.115), the
MRSA isolateswere classiﬁed as non-producers (BU≤0.230),weak pro-
ducers (BU>0.230 and ≤0.460), moderate producers (BU>0.460 and≤0.920) and strong producers (BU>0.920). Because the development
of bioﬁlm is subject to phase variation, tests were repeated eight
times. At least three independent experiments were carried out for
each test. The three highest BU values obtained for each isolate analyzed
were used for statistical calculations.
2.3. Confocal laser scanning microscopy (CLSM)
To visualize the differences observed among in vitro bioﬁlm
phenotypes, as determined by BU values, CLSM was employed to
record and contrast structural images of the bioﬁlms formed for the
agr mutant and rnaIII-complementary strain derived from isolate
NY19335. The bioﬁlm assay was performed as above with the follow-
ing modiﬁcation: after incubation (37 °C for 20 h), the supernate and
non-adherent cells were removed and the bioﬁlm formedwas treated
with 25 nM SYTO 9 DNA-intercalating stain (Invitrogen) for 15 min in
the dark. The excess of stain was gently removed from the wells and
bioﬁlm visualized using a Zeiss LSM510 metalaser scanning confocal
microscope. The microscope was inverted and conﬁgured with one
laser (argon 458 nm/477 nm/488 nm/514 nm). Images were cap-
tured at random with a Plan-Neoﬂuar 406/0.6 Korr objective. Filters
were set to a band pass of 500–530 nm.
2.4. In vitro bioﬁlm formation on surfaces covered with human ﬁbronectin
(Fn) or serum
To study the bioﬁlm formation on solid-phase Fn or serum-coated
surfaces, sterile 96-well inert polystyrene microtiter plates (Nunclon;
Nunc) were covered with 50 μg/mL human Fn (solid-phase Fn;
Merck) diluted in 0.01 M phosphate buffered saline (pH7.3; PBS) or
with 200 μL of pooled human serum obtained from healthy volun-
teers. The plate was incubated for 1 h at 37 °C and left for 18 h at
4 °C. After that, the excess of Fn or serum was carefully removed
and the wells of the Fn-coated plates were washed twice in PBS.
Washings were not performed when plates were treated with
human serum. Bioﬁlm assays were carried out as described for the
microtiter plate-based model.
2.5. In vitro bioﬁlm formation on the surface of intravenous catheter segment
The isolates BMB9393 and NY19335 (strong and weak bioﬁlm
producers on inert surface, respectively) were harvested at mid-
exponential growth phase and diluted in the same fresh broth (TSB-
1% Glc) to contain 104 colony forming units (CFU). A volume of
10 μL was injected into the lumen of a 1 cm-segment polyurethane
catheter (Cook Medical; C-UDLM-953J model). The contaminated
catheter fragment was placed into the well of a 24-well plate and
the plate incubated for 20 h. Bioﬁlm was assessed by counting
catheter-adherent bacteria. Thus, the catheter was washed twice
with 1 mL PBS, to remove non-adherent bacteria, and placed in a
tube containing 1 mL TSB. After sonication (10 min; 38.5–40.5 kHz),
the colony forming units (CFU/mL) were determined using tryptic
soy agar (TSA; BD).
2.6. In vivo bioﬁlm formation
Due to the increased (in vitro) ability of the agr mutant
MNY19335 (Δagr::tetM) to accumulate bioﬁlm on inert polystyrene
surface when compared with the isogenic wild type (WT) and
rnaIII-complemented construction (Coelho et al., 2008), this set of
bacteria represents an interesting system to challenge in vitro and
in vivo bioﬁlm models. Thus, aiming to reduce the number of animal
sacriﬁced, we opted to compare the in vitro and the in vivo ap-
proaches using this set of agr constructions in addition to a pair of
weak (the isogenic WT, NY19335) and strong (BMB9393) bioﬁlm
producers selected among the clinical MRSA isolates studied. The
Fig. 1. In vitro bioﬁlm formation/accumulation by MRSA clinical isolates. Columns
1–19: MRSA isolates from Rio de Janeiro; NY19335: MRSA clinical isolate from
Miami, Fl; BMB9393: MRSA clinical isolate displaying superior ability to form/accumu-
late bioﬁlm. A. Polystyrene inert surfaces; B. Human ﬁbronectin-coated surfaces and C.
Human serum-coated surfaces. Bioﬁlm was assessed by determining the bioﬁlm units
(BU). Data were transformed in percentage considering the BU of the isolate
BMB9393 (in each bioﬁlm model system) as the reference value (100%).
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with some modiﬁcations (Kadurugamuwa et al., 2003; Weiss et al.,
2009). For subcutaneous catheter deployment in the animal model,
young-adult BALB/c male mice (weighing approximately 30 g and
aged 6 to 8 weeks) were anesthetized with ketamine (40 mg/kg of
body weight) and thiopental (80 mg/kg). Their ﬂanks were shaved,
and the preoperative skin cleansing with tincture of iodine. A 1 cm
skin incision was made and dissected to create a subcutaneous
tunnel, into which a 1 cm segment of the intravenous polyurethane
catheter (C-UDLM-953J model; Cook Medical, Bloominaton, US) was
implanted at a distance of at least 1.5 cm from the incision. The
incision was sutured and disinfected with tincture of iodine. Two to
three catheter segments were implanted for each animal. Infection
was induced 24 h after the implantation procedure by injecting a
mid-exponential growth phase culture (106 CFU/10 μL) into the
lumen of the catheter segment on the back of anesthetized mouse.
The animal was euthanized after three or nine days post-infection,
and the catheter segments were surgically removed. Three indepen-
dent experiments were performed. Bioﬁlm was assessed by counting
catheter-adherent bacteria. Thus, the catheter segment was washed
with PBS, to remove non-adherent bacteria, and placed in a tube con-
taining 1 mL TSB. After sonication (10 min; 38.5–40.5 kHz), the
colony-forming units (CFU/mL) were determined using TSA. The ani-
mal studies were approved by The Ethics Committee for Animal Care
and Use from Federal University of Rio de Janeiro (#IMPPG013).
2.7. Statistical calculation
To analyze a possible correlation between the bioﬁlm formed on
uncoated and Fn-coated surfaces, the bioﬁlm value of each isolate test-
ed on solid-phase Fn was normalized (N) using the formula: N=BUFn/
K, where the normalization constant K=ΣBUFn/ΣBUIn; BUFn=bioﬁlm
units of each isolate tested on Fn-coated surface and BUIn=bioﬁlm
units of each isolate tested on inert (uncoated) surface (Quinn and
Keough, 2002). Student's t-test (paired data) was used to compare
the mean BU values. The null hypothesis (H0: μ=μ0) was rejected at
level α=0.05 (Dunn, 1964). For graphic representation, the results
were expressed in percentage (%) of bioﬁlm accumulation. Data were
calibrated using as reference value (100%) the BU value or the number
of adherent-bacteria (CFU/mL) of the isolate BMB9393.
3. Results
3.1. In vitro techniques
All MRSA clinical isolates tested were able to produce bioﬁlm on
inert polystyrene surfaces (Fig. 1A). In addition, these isolates could
also form/accumulate bioﬁlm on both solid-phase Fn and surfaces
coated with human serum (Fig. 1B and C). On average, the ability of
these MRSA isolates to accumulate bioﬁlm on solid-phase Fn in-
creased 3-times (Pb0.01 to Pb0.0001) when compared with that
formed on inert surfaces. However, when BU values were normalized,
in order to globally annulate the increment of the bioﬁlm accumulat-
ed on Fn-coated surfaces, the null hypothesis was accepted indicating
that there is a linear correlation between the ability of these MRSA
isolates to form/accumulate bioﬁlm on Fn-coated and uncoated poly-
styrene surfaces. Similarly to the results obtained using Fn-coated
surfaces, when microtiter plates were pre-treated with human-
serum most of the isolates displayed increased bioﬁlm accumulation.
Nevertheless, three isolates had decreased bioﬁlm accumulation and
six showed any signiﬁcant change (Fig. 1C). We have also noticed
that for a signiﬁcant number of isolates the bioﬁlm formed on
serum-covered surfaces was more detachable, easily removed by
washings, resulting in higher standard deviations (SD) and very
poor reproducibility. Consequently, this set of data was not used for
statistical proposal.As we have previously demonstrated (Coelho et al., 2008), the agr
mutation in the isolate NY19935 had a positive impact in the bioﬁlm
accumulated on polystyrene inert surface. In addition, the rnaIII-
complemented construction dropped to the level of the isogenic WT
(Fig. 2A). The CLSM experiments also conﬁrmed the impact of agr dele-
tion on bioﬁlm accumulation (Fig. 2B). The bioﬁlm values for the set
formed by WT, agr-null and rnaIII-complemented constructs also in-
creased in both plates covered with Fn and human-serum. Similarly,
the agr-mutant, which displayed superior ability to accumulate bioﬁlm
on inert surface was equally able to form a thicker bioﬁlm on coated
plates, when compared with the isogenic wild-type strain, conﬁrming
the correlation observed between these two systems (Fig. 3A, B and C).
We have also analyzed in vitro bioﬁlm formation/accumulation on
a segment of the polyurethane catheter, using a pair of strong
Fig. 2. In vitro and in vivo bioﬁlm produced by NY19335 (WT), MNY19335 (Δagr::
tetM) and CMNY19335 (Δagr::tetM, pbla–rnaIII) isolates. A. Inert polystyrene surfaces.
B. Confocal laser scanning microscopy (CLSM) and C. Foreign body mouse model: bio-
ﬁlm was assessed by counting the catheter-adhered bacteria (CFU/mL).
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ﬁlm producing clinical isolates, classiﬁed by their BU values for
uncoated surfaces (Fig. 4A), which also displayed a stronger and
weaker bioﬁlm production on coated surfaces (Fig. 4B and C). It was
veriﬁed that NY19335 also accumulated an equally poorer bioﬁlm
on the surface of the catheter segment when compared with
BMB9393 (Fig. 4D), conﬁrming once again the correlation between
inert and Fn-covered surface.3.2. In vivo technique
For comparing the in vitro systems with the foreign-body mouse
model we have initially used the set of agr constructions. AfterFig. 3. Bioﬁlm formation/accumulation of the S. aureus isolate NY19335 (WT), and the
agr constructions MNY19335 (Δagr::tetM) and CMNY19335 (Δagr::tetM, pbla–rnaIII).
A. Inert polystyrene surfaces; B. Fibronectin-coated surfaces; C. Serum-coated surfaces
and D. Foreign body mouse model. For A, B and C, bioﬁlm units (BU) were determined,
and D. Bioﬁlm was assessed by counting the catheter-adhered bacteria (CFU/mL). Data
were transformed in percentage considering the bioﬁlm values of the isolate BMB9393
(in each bioﬁlm model system) as the reference value (100%).3 days of the surgical implantation, it was observed that the bioﬁlm
formed on the implanted catheter segment contaminated with the
agr knockout increased 90% when compared with that displayed by
the WT (Pb0.01). The results obtained for the complemented agr-
construction were quite similar to that of WT (Figs. 2C and 3D).
Thus, animal data corresponded very well to those obtained using
microplate-based models (inert and coated surfaces) for the set of
agr constructions, showing that the agr mutant formed increased
amount of bioﬁlm in all in vitro and in vivo systems tested
(Fig. 3A–D).
Next, the catheter segments contaminated with clinical isolates
BMB9393 (strong bioﬁlm-producer) or NY19225 (weak producer)
were left in the animals for 9 days (Fig. 4E). The MRSA isolate show-
ing superior ability to accumulate bioﬁlm (in vitro) on polystyrene
inert surface had also maintained the same feature in vivo. When
the catheter segments were examined, the strong producer showed
3-log increase in the CFU compared with that of obtained for the
weak-bioﬁlm producer (Fig. 4E).
4. Discussion
It is well known that a large number of chronic infectious diseases
are associated with the formation of adherent, multilayered bacterial
ﬁlms. In addition, bioﬁlm-related infections often fail to respond to
antimicrobial therapy (Coenye and Nelis, 2010). In fact, the bacterial
ability to form/accumulate bioﬁlms is an important feature in the
pathogenesis of medical device-associated infections and presents a
major medical challenge (Edmiston et al., 2006; Jain and Agarwal,
2009; Kawamura et al., 2011). Despite the fact that several methods
to assess bioﬁlm formation/accumulation have been described, most
of the studies were conducted using microtiter plate-based methods
(Amaral et al., 2005; Cha et al., 2011; Kawamura et al., 2011).
However, in vitro systems may not necessarily reﬂect events that
occur in vivo during the course of an infection. One of the most unex-
pected results revealed by recent studies on S. aureus bioﬁlms was the
ﬁnding that a number of surface proteins are able to induce bioﬁlm
development/accumulation in the absence of exopolysaccharides
(O'Neill et al., 2007; Lauderdale et al., 2009; O'Neill et al., 2009). The
existence of alternative mechanisms to induce bioﬁlm development
implies that each S. aureus isolate might have specialized in the devel-
opment of a particular type of bioﬁlm matrix that would better suit
the environmental conditions (Coelho et al., 2008; Vergara-Irigaray
et al., 2009). In this study, we have compared the ability of MRSA clin-
ical isolates and a set of agr constructs to form/accumulate ica-
independent bioﬁlms using in vitro systems and a foreign body infec-
tion model in mice. Our data showed that most of the MRSA isolates
studied had the ability to accumulate moderate to strong amounts
of bioﬁlm and that bioﬁlm accumulation was effectively increased
(in vitro) in the presence of solid-phase human ﬁbronectin. Similar
results were also observed by others (Vaudaux et al., 1984;
Herrmann et al., 1988) and are consistent with several studies that
have indicated Fn-binding proteins A and B (FnBPAB) as essential
factors involved in bioﬁlm formation by S. aureus (O'Neill et al.,
2008; Vergara-Irigaray et al., 2009; Houston et al., 2011). In fact, in
vivo implanted biomaterials are rapidly coated by constituents of
the serum and surrounding matrix such as ﬁbronectin, vitronectin, ﬁ-
brinogen, laminin and collagen, among others (Vaudaux et al., 1984;
Herrmann et al., 1988). It is well known that agr RNAIII is a negative
regulator of different surface proteins including FnBPs, Spa, among
others (Novick and Geisinger, 2008). Thus, as expected, the bioﬁlm
accumulation of the agr-null construction was higher on Fn-covered
surfaces when compared with that of the WT isolate and RNAIII-
complemented construction, despite the fact that bioﬁlm accumula-
tion of the complemented mutant did not reach the levels of the
WT. It is important to mention that when the BU values from the in
vitro experiments were normalized, a linear correlation was observed
Fig. 4. Comparison of bioﬁlm formation/accumulation between the strong bioﬁlm producer BMB9393 and the weak producer NY19335. A. Inert polystyrene surfaces. The micro-
plates wells, bellow the bars, show the strong and weak bioﬁlms formed by the isolates BMB9393 (BU=3.81±0.67) and NY19335 (BU=0.39±0.19); B. Fibronectin-coated sur-
faces; C. Serum-coated surfaces; D. in vitro model of intravenous catheter-segment and E. Foreign body mouse model. For A, B and C, bioﬁlm units (BU) were determined; for D and
E, bioﬁlm was assessed by plating the catheter-adhered bacteria. Data were transformed in percentage considering the bioﬁlm values of the isolate BMB9393 (in each bioﬁlm model
system) as the reference value (100%).
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also observed that preincubation of microtiter plate with human
serum increased the bioﬁlm formation/accumulation for 9 of the
MRSA isolates studied and for the agr-null and -complemented
constructions. However, we have noticed that for many isolates
the bioﬁlm was easily detachable from the surface. Studies by
Henry-Stanley et al. (2010) have demonstrated that the adherence
of the S. aureus strain RN6390 on silastic catheters was inhibited by
the treatment of catheter surfaces with serum. Recently, working
with two S. aureus strains, ATCC 35556 and Newman, Abraham and
Jefferson (2010) have isolated a serum component of 3000 kDa that
could potently inhibit the bioﬁlm formation by these two S. aureus
strains. Thus we do not recommend the use of surfaces covered
with human serum for studying S. aureus bioﬁlm formation/
accumulation.Despite the fact that few studies have been carried out to compare
the performance of in vitro and in vivo bioﬁlm model systems (Cassat
et al., 2007; Weiss et al., 2009), the foreign body mouse model chosen
in this study had already been used with success by others
(Kadurugamuwa et al., 2003; Weiss et al., 2009). Our data with a
pair of strong and weak bioﬁlm producing clinical isolates of MRSA
also conﬁrmed a good correlation between the in vivo and in vitro ap-
proaches. The agr set was also used for challenging both systems and
again there was a good match between the in vivo and in vitro data.
Our results corroborate recent studies that have shown the impor-
tant role for ﬁbronectin-binding proteins in bioﬁlm accumulation/
maturation on polystyrene surfaces (O'Neill et al., 2008 and 2009)
and support the conclusion that microtiter plates seem to be a good
system for screening ica-independent bioﬁlms. Indeed, it was sug-
gested that the main effect of the FnBPs on bioﬁlms formed on
398 F.A. Ferreira et al. / Journal of Microbiological Methods 88 (2012) 393–398untreated surface was mainly due to their ability to promote cell–cell
adhesion rather than to support primary adhesion to those surfaces
(O'Neill et al., 2008). A clear advantage of the microtiter plate-based
system is that it permits a high throughput. Indeed, because it is
very easy to perform, this system allows researchers to test the effect
of different compounds and environmental signals on bioﬁlm
modulation (Coenye and Nelis, 2010). Cassat et al. (2007) have also
indicated that microtiter plate assays are particularly useful for com-
parison of multiple S. aureus strains, including large-scale screens of
mutant. In addition, it has been commonly used to test the effect of
antimicrobials, biocides and quorum-sensing inhibitors on bacterial
ﬁlms (Brackman et al., 2011; Cha et al., 2011). Despite that, in vivo
bioﬁlm models are essential for a better understanding of medical-
device related infections and can be very useful to test the effect of
different inhibitors, therapeutic treatments and biomaterials on bio-
ﬁlm formation/accumulation. Small animals which are easy to infect
and relatively economical are preferred in most studies (Coenye and
Nelis, 2010).
There are not so many studies in which a signiﬁcant number of
bioﬁlm models had been compared, but it seems obvious that the
selection of a system may have a marked inﬂuence on the results
(Coenye and Nelis, 2010), as it was observed for polystyrene plates
covered with human serum. This example clearly illustrates that
data obtained in different models will not necessarily match.
Concluding, the results on bioﬁlm formation/accumulation for inert
surfaces (microtiter plate-based model) showed good correlation
with those obtained for the foreign body mice model. Thus, we
recommend this in vitro model for investigating ica-independent
bioﬁlm in a large bacterial population or when numerous variables
need to be tested. Finally, because the animal model chosen here
was reproducible and relatively easy to perform, it could be useful
to conﬁrm results of a set of in vitro experimentations by a system
that better mimics the real-life situation of a natural human foreign-
body infection.
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